| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulation, Vol 82, 781-791, Copyright © 1990 by American Heart Association
EM Ohman, RM Califf, EJ Topol, R Candela, C Abbottsmith, S Ellis, KN Sigmon, D Kereiakes, B George and R Stack
To determine the clinical consequences of reocclusion of an infarct-
related artery after reperfusion therapy, we evaluated 810 patients with
acute myocardial infarction. Patients were admitted into four sequential
studies with similar entry criteria in which patency of the infarct-related
artery was assessed by coronary arteriography 90 minutes after onset of
thrombolytic therapy. Successful reperfusion was established acutely in 733
patients. Thrombolytic therapy included tissue-type plasminogen activator
(t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in
129 patients. All patients received aspirin, intravenous heparin and
nitroglycerin, and diltiazem during the recovery phase. A repeat coronary
arteriogram was performed in 88% of patients at a median of 7 days after
the onset of symptoms. Reocclusion of the infarct-related artery occurred
in 91 patients (12.4%), and 58% of these were symptomatic. Angiographic
characteristics at 90 minutes after thrombolytic therapy that were
associated with reocclusion compared with sustained coronary artery patency
were right coronary infarct-related artery (65% versus 44%, respectively)
and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21% versus
10%, respectively) before further intervention. Median (interquartile
value) degree of stenosis in the infarct-related artery at 90 minutes was
similar between groups: 99% for reoccluded (value, 90/100%) compared with
95% for patent (value, 80/99%). Patients with reocclusion had similar left
ventricular ejection fractions compared with patients with sustained
patency at follow-up. However, patients with reocclusion at follow-up had
worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4
(SD/chord) (value, -3.1/-1.3) (p = 0.016). The recovery of both global and
infarct-zone function was impaired by reocclusion of the infarct-related
artery compared with maintained patency; median delta ejection fraction was
-2 compared with 1 (p = 0.006) and median delta infarct-zone wall motion
was -0.10 compared with 0.34 SD/chord (p = 0.011), respectively. In
addition, patients with reocclusion had more complicated hospital courses
and higher in-hospital mortality rates (11.0% versus 4.5%, respectively; p
= 0.01). We conclude that reocclusion of the infarct-related artery after
successful reperfusion is associated with substantial morbidity and
mortality rates. Reocclusion is also detrimental to the functional recovery
of both global and infarct-zone regional left ventricular function. Thus,
new strategies in the postinfarction period need to be developed to prevent
reocclusion of the infarct-related artery.
ARTICLES
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
This article has been cited by other articles:
 |
|
 |
|
  G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention Circulation, July 29, 2008; 118(5): 538 - 551. [Full Text] [PDF]
|
|
|
|
|
|
E. R. Bates and B. K. Nallamothu Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction Circulation, July 29, 2008; 118(5): 567 - 573. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Le May, D. Y. So, R. Dionne, C. A. Glover, M. P.V. Froeschl, G. A. Wells, R. F. Davies, H. L. Sherrard, J. Maloney, J.-F. Marquis, et al. A Citywide Protocol for Primary PCI in ST-Segment Elevation Myocardial Infarction N. Engl. J. Med., January 17, 2008; 358(3): 231 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Scirica, D. A. Morrow, Z. Sadowski, M. Ruda, J. C. Nicolau, R. P. Giugliano, S. D. Wiviott, M. S. Sabatine, A. Shui, E. M. Antman, et al. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study Eur. Heart J., September 1, 2007; 28(17): 2070 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fernandez-Aviles, J. J. Alonso, G. Pena, J. Blanco, J. Alonso-Briales, J. Lopez-Mesa, F. Fernandez-Vazquez, J. Moreu, R. A. Hernandez, A. Castro-Beiras, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial Eur. Heart J., April 2, 2007; 28(8): 949 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Sabatine Clopidogrel in ST-elevation myocardial infarction Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G31 - G34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Scirica, M. S. Sabatine, D. A. Morrow, C. M. Gibson, S. A. Murphy, S. D. Wiviott, R. P. Giugliano, C. H. McCabe, C. P. Cannon, and E. Braunwald The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: The ECG CLARITY-TIMI 28 Study J. Am. Coll. Cardiol., July 4, 2006; 48(1): 37 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, D. A. Morrow, C. H. McCabe, S. A. Murphy, M. Ruda, Z. Sadowski, A. Budaj, J. L. Lopez-Sendon, S. Guneri, F. Jiang, et al. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction N. Engl. J. Med., April 6, 2006; 354(14): 1477 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, G. Montalescot, M. Dellborg, J. L. Leiva-Pons, M. Keltai, S. A. Murphy, C. H. McCabe, C. M. Gibson, C. P. Cannon, et al. Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial Circulation, December 20, 2005; 112(25): 3846 - 3854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Le May, G. A. Wells, M. Labinaz, R. F. Davies, M. Turek, D. Leddy, J. Maloney, T. McKibbin, B. Quinn, R. S. Beanlands, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study) J. Am. Coll. Cardiol., August 2, 2005; 46(3): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rubiera, J. Alvarez-Sabin, M. Ribo, J. Montaner, E. Santamarina, J. F. Arenillas, R. Huertas, P. Delgado, F. Purroy, and C. A. Molina Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke Stroke, July 1, 2005; 36(7): 1452 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, M. J. Claeys, F. Cools, K. A. Hill, A. M. Skene, et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation N. Engl. J. Med., March 24, 2005; 352(12): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Marin, R. Gonzalez-Conejero, K. W. Lee, J. Corral, V. Roldan, F. Lopez, F. Sogorb, J. Caturla, G. Y.H. Lip, and V. Vicente A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction J. Am. Coll. Cardiol., January 4, 2005; 45(1): 25 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Rubenstein, A. V. Finn, R. C. Leinbach, S. Hollenbach, H. T. Aretz, R. Virmani, and H. K. Gold Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury J. Am. Coll. Cardiol., January 21, 2004; 43(2): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bjorklund, B. Lindahl, P. Johanson, T. Jernberg, A.-M. Svensson, P. Venge, L. Wallentin, M. Dellborg, and the ASSENT-2 and ASSENT-PLUS study groups Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction Eur. Heart J., January 2, 2004; 25(2): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Topaz, E. C. Perin, R. L. Jesse, P. K. Mohanty, M. Carr, and U. Rosenschein Power Thrombectomy in Acute Ischemic Coronary Syndromes Angiology, July 1, 2003; 54(4): 457 - 468. [Abstract] [PDF]
|
|
|
|
|
|
M. C. Tjandrawidjaja, Y. Fu, S. G. Goodman, F. Van de Werf, C. B. Granger, P. W. Armstrong, and for the ASSENT-2 Investigators The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2{star} Eur. Heart J., June 1, 2003; 24(11): 1024 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Heo, K. Y. Lee, S. H. Kim, and D. I. Kim Immediate reocclusion following a successful thrombolysis in acute stroke: A pilot study Neurology, May 27, 2003; 60(10): 1684 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lincoff, R. M. Califf, F. Van de Werf, J. T. Willerson, H. D. White, P. W. Armstrong, V. Guetta, W. B. Gibler, J. S. Hochman, C. Bode, et al. Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial JAMA, November 6, 2002; 288(17): 2130 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ronner, R.T. van Domburg, M.J.B.M. van den Brand, P.J. de Feyter, D.P. Foley, W.J. van der Giessen, P.W. Serruys, and M.L. Simoons Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies. A single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction Eur. Heart J., October 1, 2002; 23(19): 1529 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Brouwer, P. J.P.C. van den Bergh, W. R.M. Aengevaeren, G. Veen, H. E. Luijten, D. P. Hertzberger, A. J. van Boven, R. P.J.W. Vromans, G. J.H. Uijen, and F. W.A. Verheugt Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Circulation, August 6, 2002; 106(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. de Lemos and E. Braunwald ST segment resolution as a tool for assessing the efficacy of reperfusion therapy J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1283 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hudson, C. B. Granger, E. J. Topol, K. S. Pieper, P. W. Armstrong, G. I. Barbash, A. D. Guerci, A. Vahanian, R. M. Califf, and E. M. Ohman Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials Circulation, September 11, 2001; 104(11): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Loubeyre, T Lefevre, Y Louvard, P Dumas, J.-F Piechaud, J.-J Lanore, J.-F Angellier, J.-Y Le Tarnec, G Karrillon, A Margenet, et al. Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent Eur. Heart J., July 1, 2001; 22(13): 1128 - 1135. [Abstract] [PDF]
|
|
|
|
|
|
H.C. Herrmann, R.H. Li, and E.M. Ohman Facilitated percutaneous coronary intervention: results from the SPEED trial Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A26 - A34. [Abstract] [PDF]
|
|
|
|
|
|
G. I. Barbash, Y. Birnbaum, K. Bogaerts, M. Hudson, E. Lesaffre, Y. Fu, S. Goodman, K. Houbracken, K. Munsters, C. B. Granger, et al. Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction : An Analysis of Outcome and Treatment Choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) Studies Circulation, February 20, 2001; 103(7): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119(1_suppl): 253S - 277S. [Full Text] [PDF]
|
|
|
|
|
|
P.W. Armstrong Reperfusion synergism: will it be both sustained and safe? Eur. Heart J., December 1, 2000; 21(23): 1913 - 1916. [PDF]
|
|
|
|
|
|
R. Wilcox Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy Eur. Heart J., September 2, 2000; 21(18): 1495 - 1497. [PDF]
|
|
|
|
|
|
J. G. Canto, M. G. Shlipak, W. J. Rogers, J. A. Malmgren, P. D. Frederick, C. T. Lambrew, J. P. Ornato, H. V. Barron, and C. I. Kiefe Prevalence, Clinical Characteristics, and Mortality Among Patients With Myocardial Infarction Presenting Without Chest Pain JAMA, June 28, 2000; 283(24): 3223 - 3229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Diamantopoulos, D. Charitos, V. Georgopoulos, E. Economou, M. Sfakianakis, P. Toutouzas, and S. Raptis Oxygen Free Radicals and the Effect of a Free Radical Scavenger in Patients with Intermittent Claudication Vascular and Endovascular Surgery, March 1, 2000; 34(2): 167 - 174. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF]
|
|
|
|
 |
|
 I. B A Menown and A A J. Adgey Improving reperfusion after myocardial infarction BMJ, December 11, 1999; 319(7224): 1513 - 1515. [Full Text]
|
|
|
|
|
|
E. C. Keeley and W. D. Weaver Combination therapy for acute myocardial infarction J. Am. Coll. Cardiol., December 1, 1999; 34(7): 1963 - 1965. [Full Text] [PDF]
|
|
|
|
|
|
K.-L. Neuhaus, G. P. Molhoek, U. Zeymer, U. Tebbe, K. Wegscheider, R. Schroder, A. Camez, G. J. Laarman, G. M. Grollier, D. J. A. Lok, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial J. Am. Coll. Cardiol., October 1, 1999; 34(4): 966 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-K. Jang, D. F. M. Brown, R. P. Giugliano, H. V. Anderson, D. Losordo, J. C. Nicolau, O. P. Dutra, O. Bazzino, V. M. Viamonte, R. Norbady, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1879 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, R. P. Giugliano, C. M. Gibson, C. H. McCabe, P. Coussement, N. S. Kleiman, A. Vahanian, A. A. J. Adgey, I. Menown, H.-J. Rupprecht, et al. Abciximab Facilitates the Rate and Extent of Thrombolysis : Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial Circulation, June 1, 1999; 99(21): 2720 - 2732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Gibson Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting Ann Intern Med, May 18, 1999; 130(10): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Scanlon, D. P. Faxon, A.-M. Audet, B. Carabello, G. J. Dehmer, K. A. Eagle, R. D. Legako, D. F. Leon, J. A. Murray, S. E. Nissen, et al. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1756 - 1824. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Szarka, E. G. Sihota, H. R. Habibi, and S.-L. Wong Staphylokinase as a Plasminogen Activator Component in Recombinant Fusion Proteins Appl. Envir. Microbiol., February 1, 1999; 65(2): 506 - 513. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Bates and J. I. Weitz Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin Cardiovasc Res, February 1, 1999; 41(2): 418 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Horie, M. Takahashi, K. Minai, M. Izumi, A. Takaoka, M. Nozawa, H. Yokohama, T. Fujita, T. Sakamoto, O. Kito, et al. Long-Term Beneficial Effect of Late Reperfusion for Acute Anterior Myocardial Infarction With Percutaneous Transluminal Coronary Angioplasty Circulation, December 1, 1998; 98(22): 2377 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Theroux, J. Gregoire, C. Chin, G. Pelletier, P. de Guise, and M. Juneau Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial J. Am. Coll. Cardiol., September 1, 1998; 32(3): 620 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maki, C. Shirato, M. Ohguchi, N. Aoki, N. Ochiai, S. Taguchi, I. Aoki, and K. Ishikawa Mechanism of Rethrombosis After Thrombolytic Therapy: Angioscopic Findings and Investigation of the Coagulation System in Dogs Angiology, June 1, 1998; 49(6): 447 - 453. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Barrabes, D. Garcia-Dorado, M. A. Gonzalez, M. Ruiz-Meana, J. Solares, Y. Puigfel, and J. Soler-Soler Regional expansion during myocardial ischemia predicts ventricular fibrillation and coronary reocclusion Am J Physiol Heart Circ Physiol, May 1, 1998; 274(5): H1767 - H1775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White and F. J. J. Van de Werf Thrombolysis for Acute Myocardial Infarction Circulation, April 28, 1998; 97(16): 1632 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White, P. E. Aylward, M. J. Frey, A. A. J. Adgey, R. Nair, W. S. Hillis, Y. Shalev, M. A. Brown, J. K. French, R. Collins, et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) Circulation, October 7, 1997; 96(7): 2155 - 2161. [Abstract] [Full Text]
|
|
|
|
|
|
F. Nijland, O. Kamp, F. W.A. Verheugt, G. Veen, and C. A. Visser Long-term Implications of Reocclusion on Left Ventricular Size and Function After Successful Thrombolysis for First Anterior Myocardial Infarction Circulation, January 7, 1997; 95(1): 111 - 117. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. Ohman, P. W. Armstrong, R. H. Christenson, C. B. Granger, H. A. Katus, C. W. Hamm, M. A. O'Hanesian, G. S. Wagner, N. S. Kleiman, F. E. Harrell, et al. Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia N. Engl. J. Med., October 31, 1996; 335(18): 1333 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial Circulation, September 1, 1996; 94(5): 911 - 921. [Abstract] [Full Text]
|
|
|
|
|
|
A. Mortara, G. Specchia, M. T. La Rovere, J. T. Bigger Jr, F. I. Marcus, J. A. Camm, S. H. Hohnloser, R. Nohara, and P. J. Schwartz Patency of Infarct-Related Artery : Effect of Restoration of Anterograde Flow on Vagal Reflexes Circulation, March 15, 1996; 93(6): 1114 - 1122. [Abstract] [Full Text]
|
|
|
|
|
|
S.-K. Yao, S. Akhtar, T. Scott-Burden, J. C. Ober, P. Golino, L. M. Buja, W. Casscells, and J. T. Willerson Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis Circulation, August 15, 1995; 92(4): 1005 - 1010. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Smalling, C. Bode, J. Kalbfleisch, S. Sen, P. Limbourg, F. Forycki, G. Habib, R. Feldman, S. Hohnloser, and A. Seals More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction Circulation, June 1, 1995; 91(11): 2725 - 2732. [Abstract] [Full Text]
|
|
|
|
|
|
T. Brzostek, F. Van de Werf, I. Scheys, L. Mortelmans, A. Aubert, J. S. Dubiel, and H. De Geest Determinants of Left Ventricular Function Two Weeks and One Year After an Acute Myocardial Infarction Angiology, January 1, 1995; 46(1): 27 - 36. [Abstract] [PDF]
|
|